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Introduction
Parkinson’s disease (PD), first described by James
Parkinson in 1817, is a chronic, progressive neurodegen-
erative disorder1. The pathologic hallmark is a deterio-
ration of the substantia nigra of yet unknown causes,
resulting in a deficiency of dopamine, an important
neurotransmitter for the basal ganglia circuit. Its typical
clinical symptoms are resting tremor, cogwheel rigidity,
bradykinesia, and postural instability. Many affected
patients are older than 55 years of age, and men seem to
be slightly more predominantly affected than women2.
While PD is mainly regarded as a movement disor-
der, patients suffer from not only motor symptoms,
but also the non-motor symptoms which are also 
common and can significantly debilitate patients’ activ-
ities as well as the quality of life. These complications
include cognitive, psychiatric, autonomic, sleep and
sensory disorders (Table). The non-motor symptoms
may appear even before the motor symptoms are first
noticed. But they are more troublesome in the more
advanced stages of PD, when they can become major
problems for the patients and often pose a challenge
to the treating physicians3,4. With multiple medications
often being used to treat PD, their side effects may 
further exacerbate the problems.
Epidemiology
Because of the varieties of symptoms, the prevalence of
non-motor symptoms in PD patients is difficult to delin-
eate precisely. It is estimated that about 16–70% of
patients suffer from neuropsychiatric problems, includ-
ing depression, anxiety, apathy or psychosis5–7. Cogni-
tive deficits affect at least 20–40% of PD patients8–10.
Sleep disturbances occur in more than a third of PD
patients11,12. Dysautonomia, including constipation,
orthostatic hypotension, urinary and sexual dysfunc-
tions, is reported in more than half of the PD patients,
according to a questionnaire-based study13. This Euro-
pean study and other studies also suggest that auto-
nomic failures, including orthostatic dizziness, bladder
dysfunctions, erectile dysfunctions and hyperhidrosis, are
more prevalent in PD patients than control individuals
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without PD. These symptoms had a huge impact on
their quality of life13–15. Using a comprehensive symp-
tom survey, Siddiqui et al.16 reported a significantly
higher prevalence rate of increased salivation, dyspha-
gia, decreased bowel movement, and orthostatic dizzi-
ness in PD patients compared with controls. Two
studies showed that cardiac uptake of metaiodobenzyl-
guanidine, an index of functional integrity and func-
tion of postganglionic neurons, was impaired in almost
all patients with PD, independent of duration and sever-
ity of their parkinsonian symptoms17,18.
Pathophysiology
Since non-motor symptoms comprise a variety of
symptoms in different aspects, their involvement must
be related to diffuse or multiple brain dysfunctions.
Hallucination and psychosis can be related to the do-
paminergic system in the prefrontal region. Depression
is likely due to the decreased numbers of serotonin 
5-hydroxyindolacetic acid (5-HT) neurons in the dorsal
raphe nucleus and reduced dopamine neurons in the
ventral tegmental area19,20. Cognitive function may be
related to the depletion of dopamine in the head of
the caudate nucleus, which participates in the basal
ganglia-thalamocortical circuits involving different
regions of the prefrontal cortex. Lewy body formation
is abundant in these regions21,22. Urinary control may be
from frontal cortex degeneration or autonomic nervous
system dysfunction, and possibly in combination with
prostate enlargement. Orthostatic hypotension is likely
due to sympathetic denervation of the central control
centers located at the dorsal vagal nucleus, nucleus
ambiguus, and other medullary centers (caudal raphe
nuclei, rostral ventrolateral medulla, and ventromedial
medulla). These nuclei mainly control the sympathetic
pre-ganglionic neurons via descending pathways23,24.
Lewy bodies have been found in the myenteric plexus in
PD patients. This explains the reason for constipation
because of the loss of dopaminergic cells throughout
the gastrointestinal tract25.
PD is characterized by a dopaminergic degenera-
tive process affecting neurons in the substantia nigra.
This results in the disruption in the basal ganglia cir-
cuitry. How the degenerative processes damage both
the nigrostriatal system and other brain regions is not
completely clear. Braak et al.26 hypothesized that the
degenerative process starts from the base of the brain.
The olfactory bulbs may be the first to be involved, 
followed by the lower brain stem that affects autonomic
functions as well as sleep. Subsequently, substantia nigra
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Table. The non-motor symptom complex of Parkinson’s disease
Neuropsychiatric Sensory and 
symptoms
Sleep disorders Autonomic symptoms
other symptoms
(A) Depression, apathy, (A) REM sleep behavior (A) Cardiovascular system: orthostatic (A) Pain
anxiety disorder and REM loss hypotension; falls related to (B) Paraesthesia
(B) Compulsive-obsessive of atonia orthostatic hypotension; bradycardia (C) Olfactory 
behavior (possibly (B) Non-REM-sleep related or arrhythmia disturbance
drug induced), movement disorders (B) Gastrointestinal system: sialorrhea; (D) Fatigue
repetitive behavior (C) Insomnia dysphagia and choking; reflux, (E) Weight 
(C) Attention deficit (D) Excessive daytime vomiting, nausea; fecal constipation; changes
(D) Hallucinations, somnolence fecal incontinence
illusion, delusions (E) Restless legs and periodic (C) Urinary system: bladder 
(E) Delirium limb movements disturbances; urgency and 
(F) Anxiety and panic (F) Nightmares or vivid dreams frequency; nocturia; incontinence
attacks (G) Sleep disordered breathing (D) Reproductive system: sexual 
(G) Dementia (sleep apnea) dysfunction; erectile impotence; 
hypersexuality (possibly drug induced)
(E) Thermoregulation: sweating; dry 
eyes (xerostomia); heat or 
cold intolerance
Modified from Chaudhuri et al.3. REM = rapid eye movement.
and other nuclei in the midbrain are affected, thus man-
ifesting the typical motor symptoms of PD. Eventually,
the limbic system and frontal neocortex are involved,
resulting in cognitive and psychiatric symptoms in the
advanced PD stages. Although yet to be confirmed,
Braak et al.’s hypothesis nicely illustrates the evolving
symptoms in PD, including both motor and non-motor
manifestations26–28.
Depression
Depression is a very common feature in patients with
PD. The reported prevalence from various studies is
between 16% and 70%5–7. Such variations are due to
the different diagnostic criteria used in different studies.
Major depressive disorder defined by DSM-IV may not
be very common in PD patients, but depressive symp-
toms certainly have a high prevalence rate in PD. It is
thought that complex interactions between norepi-
nephrine, serotonin and dopamine systems are inter-
rupted in brains of PD patients. The mechanisms are not
clear yet. Some studies revealed decreased concentra-
tions of 5-HT, a serotonin metabolite, in the cere-
brospinal fluid and reduced cortical 5-HT1A receptor
binding in PD29. Another study suggested the role of
an allelic variation in the serotonin transporter gene30.
The diagnosis of depression in PD can be challeng-
ing, since flat affect, psychomotor slowing, fatigue, and
decreased libido may be frequently mistaken for PD
motor symptoms. The characteristics of depression in
PD are decreased energy and motivation, losing interest,
feelings of sadness, helplessness and hopelessness,
changes in weight, sleep and appetite, irritability, and
thoughts of suicide. Approximately 7–32% of PD patients
are diagnosed with major depression, according to
DSM-IV diagnostic criteria31. However, the depression
is reported to be qualitatively different in that many
depressed PD patients have greater rates of anxiety, pes-
simism, irrationality, and less guilt and self-reproach,
compared with those of non-PD patients with major
depression32,33. There can be fluctuations between a
normal affect and a depressive state in their emotions.
The episodes of depression may be more frequent dur-
ing the “off” medication stage and may improve when
the motor symptoms are better treated34. Interestingly,
depression has been found to be more prevalent in
patients with the akinetic-rigid type of PD, compared
with those with the tremor-predominant type, and in
patients with right-sided motor symptoms35,36. Further-
more, greater depression is probably associated with
greater motor symptom severity in PD37.
Reactive depression is another form of depression
experienced by newly diagnosed PD patients and others
with more advanced disease who are losing independ-
ence and control because of changes in motor func-
tioning and feelings of helplessness6,25. Other social
factors, including job loss with subsequent changes in
income or loss of identity, may also contribute to depres-
sion. Concurrent memory difficulty, communication
problems, and sleep interruptions, all add to the severity
of depression and anxiety. They contribute substantially
to increased morbidity and caregiver burdens.
Treating PD patients with depression has not been
different from treating patients with other forms of
depressive disorders. Selective serotonin reuptake inhib-
itors (SSRIs) are most frequently used. This is generally
safe, although a small number of patients were reported
to develop serotonin syndrome from combined use of
SSRI and selegiline, a monoamine oxidase B inhibitor38.
The effectiveness of SSRI in the treatment of PD
depression is still not determined. There have not been
large-scale, of double-blind, placebo-controlled studies
conducted. A meta-analysis found disappointing bene-
fits of SSRI treatment in older PD patients with depres-
sion39. Other treatments of choice include tricyclic
antidepressants. While this class of medications has the
additional benefit in reducing tremor by their anti-
cholinergic action, the side effects, including confusion,
orthostatic hypotension, dry mouth or constipation,
often limit their use. Rarely, electroconvulsive therapy is
used in patients with medication-refractory depression.
It may improve motor function in PD patients40,41.
Anxiety
There can be periodic anxiety and panic attacks. Anxiety
disorders are more prevalent in PD patients than 
age-matched controls, although it is often under-
diagnosed42. The prevalence rate is at least 40%43. Panic
attacks easily occur in patients who develop erratic
motor fluctuations during “off” periods. It usually
improves after the patient achieves the “on” state44. “On”
state dyskinesia may also induce anxiety. Thus, anxiety
attacks seem more related with the motor fluctuations
in PD patients. Benzodiazepine, buspirone, and SSRI
may help reduce such anxiety45. However, better control
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of PD motor symptoms may be more helpful in reduc-
ing anxiety and fearfulness.
Cognitive Decline and Dementia
Dementia in PD may not be evident until the later
stages. Although the cognitive decline reported in PD
is subtle and does not often interfere with daily func-
tioning, PD patients have been shown to demonstrate
cognitive slowing and executive dysfunctioning prob-
lems at earlier stages46. Longitudinal research has
described PD-related cognitive deficits in language,
visuospatial functioning, long-term memory, and execu-
tive functioning that are greater than those expected
from normal aging. The percentage of patients with
cognitive deficits is estimated to be approximately
20%8,10. However, the prevalence varies widely according
to different studies. For example, a Norwegian study
of PD patients indicated that the 8-year prevalence in
developing dementia was 78.2%47.
The cognitive dysfunction in PD may be a conse-
quence of disruption not only in the primary motor
circuit but also in a number of interconnected path-
ways from the basal ganglia to the cortex. Dopamine
depletion in the lateral orbitofrontal and dorsolateral
prefrontal circuits has been suggested as a possible
mechanism of cognitive impairment in PD48. Cholinergic
cell loss in the nucleus basalis of Meynert is prominent
in PD. The disturbances of dopamine–acetylcholine
dependent alterations in synaptic plasticity may also
be responsible for dementia in PD49.
PD patients at a higher risk of developing demenia
include: (1) age older than 70 years; (2) Unified Parkin-
son’s Disease Rating Scale motor score of more than
25 (moderate to advanced impairment); (3) coexisting
depression; (4) development of mania, agitation, dis-
orientation or psychosis when treated with levodopa;
(5) facial masking at presentation; (6) exposure to psy-
chologic stress; (7) presence of cardiovascular abnor-
malities; (8) low socioeconomic status and educational
level; and (9) predominant bradykinesia, and postural
and gait disturbance. Tremor or other parkinsonian
signs are less associated with dementia10,50,51.
Cognitive impairment in PD is usually distinguished
from that of Alzheimer’s type, which reveals more
amnestic quality of memory loss. In contrast, PD patients
encompass the clinical symptoms of cognitive slowing,
impaired memory recall and retrieval, and executive
deficits. These symptoms are summarized as “dysexecu-
tive syndrome”, in which acquisition and delayed recall
are defective, while recognition memory remains intact52.
However, the distinctions usually may not be very clear.
About 15–30% of demented patients with PD may also
have coexisting Alzheimer’s disease and exhibit symp-
toms of impaired language, memory, and visuospatial
functioning earlier in the course of the disease, includ-
ing the presence of aphasia, agnosia, and apraxia53,54.
Another important differential diagnosis is dementia
with Lewy bodies (DLBs), which also manifests demen-
tia, autonomic failure, and parkinsonian symptoms.
As a general rule, DLB patients show fluctuations in men-
tal symptoms, visual hallucinations, and more promi-
nent lower body parkinsonism. The motor symptoms
of parkinsonism usually occur together with cognitive
decline55. Again, the clinical features are frequently
not reliable in making a clear differentiation. A con-
firmed diagnosis usually depends on the results of
autopsy. A typical pathologic picture of DLBs shows
widespread Lewy bodies located in the neocortex and
basal ganglia56.
Rivastigmine, an acetylcholinesterase inhibitor that
has been used in the symptomatic treatment of patients
with mild to moderate Alzheimer’s disease, was also
shown to be effective in the treatment of dementia in
PD57,58. Other cholinesterase inhibitors may also be
beneficial, although large-scale randomized controlled
studies have yet to be conducted59. Memantine, which
is an N-methyl-D-aspartate receptor antagonist benefi-
cial in Alzheimer’s dementia, has not been shown to
be effective in PD dementia60. One study even sug-
gested that it worsened both the motor and cognitive
functions in PD61.
Psychosis and Hallucination
Hallucination occurs in PD, more frequently in the
advanced stages. Psychosis and visual hallucination
are common, dose-dependent adverse effects of anti-PD
medications, in combination with disease progression
and medical illnesses62. Risk factors include advancing
age, presence of dementia, and polypharmacy. Patients
who experience hallucination generally have a certain
degree of cognitive decline. They also have a worse
prognosis, with higher mortality rates63. In addition,
delusions, paranoid ideation, and delirium may also
become more frequent as the disease progresses.
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Hallucination is usually visual in nature, in contrast
to auditory hallucination in schizophrenia64. Patients
may report seeing small animals, insects, children, or
their deceased relatives or friends. In the early stages,
patients retain insight that the hallucinations are not
real. Symptoms are commonly more severe toward
the evening, known as “sun-downing”65. Patients may
experience frightening dreams or night terrors that can
lead to acting or lashing out during the dream state.
Another common delusion is that of spousal infidelity,
for either male or female patients64,66. These symptoms
can be aggravated by dopaminergic and other psychoac-
tive medications. Any medical illness, even as mild as
an upper respiratory tract infection or diarrhea, may
trigger or worsen the demented or psychotic symp-
toms. They are best managed by either simplifying the
patient’s psychoactive medications or reducing the
dopaminergic drugs.
Typical neuroleptics significantly increase extrapyra-
midal symptoms in PD and should not be used.
Atypical neuroleptics, such as quetiapine or clozapine,
may be used in the evening to relieve such symp-
toms67–69. However, not all atypical neuroleptics are safe
or free from extrapyramidal side effects. Olanzapine
and risperidone were both shown to worsen the
motor symptoms in PD and should not be used70,71.
Sleep Disturbance
Sleep disturbances are common problems in PD
patients. Because of depression and/or hallucination,
patients may become restless at night and have diffi-
culty falling asleep. Those at higher risk for pathologic
sleep are male patients with advanced disease, cognitive
impairment, drug-induced psychosis, and orthostatic
hypotension72. After falling asleep, patients may still
wake up frequently because of stiffness of their bodies
or urinary urgency at night. As a result, they have diffi-
culty achieving restful sleep.
Rapid eye movement (REM) behavior sleep disor-
der (RBD) is very likely to occur. It is characterized by
loss of atonia during REM sleep, resulting in excess
motor activity during dreaming. It is highly related to
neurodegenerative disorders, including PD73,74. Recent
studies suggested RBD may occur well before the
emergence of PD symptoms. Approximately half of the
patients with RBD will eventually develop PD, and 
so RBD may be an indicator of presymptomatic PD75.
Interestingly, the movements during REM sleep show
little signs of parkinsonism. This could be attributed 
to the motor signals from the cortex during REM sleep
bypassing the extrapyramidal system76. Management
of this disorder requires adjusting dopaminergic med-
ications to smaller dosages, especially toward the night.
Long-acting dopamine agonists may also be consid-
ered77,78. Clonazepam has been widely used in this con-
dition, but side effects such as excessive sedation have
to be monitored72.
Excessive daytime sleepiness (EDS) is common. In
addition to fatigue that many PD patients experience,
the lack of sleep during the night also sets up a vicious
cycle for poor sleep hygiene. This sleepiness can be
disabling, often approaching levels observed in dis-
orders of sudden-onset sleep, namely narcolepsy/
cataplexy. Polysomnographic studies have shown tran-
sition from wakefulness to stage II sleep within sec-
onds79. In addition, dopaminergic drugs, especially
dopamine agonists, can further cause sedation and sud-
den onset of sleep80–82. Management is usually by adjust-
ing the timing of medications, or breaking the vicious
cycle by improving patients’ night-time sleep. Modafinil
may help relieve EDS. However, while this medicine does
not deteriorate PD symptoms, several randomized
controlled trials revealed that it either had no significant
benefit or produced only modest improvement83–85.
A significant portion of patients may suffer restless
leg syndrome (RLS) that results in sleep disturbance86–88.
It is characterized by an uncomfortable feeling of the
lower extremities that urges the patients to move. It
occurs mostly when patients are at rest or during the
night. Moving or walking will help patients feel better
subjectively. It often occurs in combination with the
symptoms of periodic limb movement during sleep, a
repetitive, myoclonic jerky limb movement present
mainly when patients are asleep. Both conditions
severely affect the sleep quality of patients. Prevalence
of RLS in PD patients was reported to be higher than
that in other non-PD patients3,89,90. The pathophysiology
is still unclear, although various central dopaminergic
systems are believed to be involved in both PD and RLS91.
Dopamine agonists, such as ropinirole and pramipexole,
are effective in controlling RLS92–95. Levodopa is also
effective in controlling the symptoms, although augmen-
tation is a concern. This limits the usefulness of levodopa
as a first-line choice for treatment of RLS. Other med-
ications, including gabapentin, clonazepam and opi-
ates, have been shown to relieve RLS symptoms96–98.
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One study even reported that deep brain stimulation
of the subthalamic nucleus also improved RLS99.
Autonomic Dysfunctions
Autonomic dysfunctions in PD patients are manifested
in several different systemic symptoms. These gener-
ally include cardiovascular (orthostatic hypotension,
cardiac arrhythmia), gastrointestinal (gastric dysmotil-
ity, indigestion, constipation, and regurgitation), urinary
(frequency, urgency or incontinence), sexual (impotence
or hypersexual drive), and thermoregulatory (exces-
sive sweating or intolerance of heat or cold) dysfunc-
tions4,25. The pathophysiology of dysautonomia in PD is
thought to be from degeneration and dysfunction of
the nuclei that mediate autonomic functions, such as the
dorsal vagal nucleus, nucleus ambiguus, and other
medullary centers (rostral ventrolateral medulla, ven-
tromedial medulla, caudal raphe nuclei), which exert
differential control on the sympathetic preganglionic
neurons via descending pathways100.
Cardiovascular System
Orthostatic hypotension is a particular concern. The
symptoms include position-related dizziness, fatigue
or even fainting. Position-related dizziness often leads
to falls in PD patients. It may be a subtle sign in the early
stage of PD and may not manifest as a major problem
until later stages101. Dopaminergic medications usually
do not significantly help. They may even worsen the
symptoms, especially with dopamine agonists102,103.
Treatment of orthostatic hypotension is mostly symp-
tomatic. For those patients who also take regular anti-
hypertensive medications, the balance between these
and Parkinson medications should be sought. Patients
are encouraged to drink appropriate amounts of water
and consume more salt. They should be taught to get up
slowly from a sitting position and wait for a while before
initiating their gait to prevent the sudden decrease of
blood pressure on positional changes. Compression
stockings may also improve the condition. In more
severe cases, antihypotensive medications may be nec-
essary to improve orthostatic hypotension symptoms.
The commonly used drugs are fludrocortisone (a salt-
retaining mineralocorticoid) or midodrine (a selective,
peripherally acting alpha-adrenergic agonist). In an epi-
demiologic study, 9.1% of PD patients required such
medications to treat orthostatic hypotension104.
Gastrointestinal System
Gastrointestinal symptoms are a common problem in
PD. Dysphagia, heartburn, medication-related nausea,
and constipation are the predominant symptoms105.
Constipation is the most frequently encountered prob-
lem. It can be one of the early signs even before the
appearance of the motor symptoms of PD13,106. Slower
bowel movement and decreased mobility exacerbate
the severity of constipation. This can especially be a
serious problem for older patients, as they do not
exercise enough and may not take adequate amounts
of fluid. At least 59% of PD patients suffer from consti-
pation as compared with 21% in age-matched non-PD
patients107. Byrne et al.108 reported that constipation
in PD is commonly a consequence of anorectal sphinc-
ter and pelvic floor dysfunctions108. Fewer than three
bowel passages in a week will raise the clinicians’ con-
cern for constipation. Patients are advised to take plenty
of high-fiber food (dietary bulk) and fluid. Reducing
anticholinergic medications will also help. Regular exer-
cise can improve bowel motility. Stool softeners, laxa-
tives, and enemas may also be used to relieve persistent
symptoms109,110.
Dysphagia may become more problematic as PD
progresses and can lead to choking and aspiration pneu-
monia. Softening of foods may help, whereas others
may need to thicken their liquids. Evaluation by a speech
pathologist or otolaryngologist can be helpful. Patients
are instructed not to rush, and to eat and chew thor-
oughly before swallowing111. However, for some patients
with advanced disease, a feeding gastrostomy may be
necessary to improve nutrition and quality of life and
avoid aspiration112.
Nausea troubles many PD patients, especially when
they suffer the side effects of levodopa, dopamine
agonists or other parkinsonian medications. This can
be explained by the stimulation of dopaminergic
receptors in the brain stem nausea center and the
peripheral tissues, including receptors on the gastroin-
testinal tract, resulting in irregular peristalsis. To cor-
rect this condition, sometimes simply changing the
medication schedule may help. Other options include
extra carbidopa to block the conversion of levodopa
to dopamine in the peripheral tissues more effectively.
Certain antiemetic (or appetite-increasing) medications,
like chlorpromazine, cisapride or metoclopramide,
block dopaminergic receptors both peripherally and
centrally and should be avoided as they will cause
worsening of PD symptoms113.
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Urinary and Sexual Systems
Urinary urgency or incontinence due to a spastic bladder
occurs in approximately 27–39% of PD patients114. A
questionnaire-based study regarding autonomic func-
tions of PD patients versus a control group of elderly
non-PD subjects found the PD patients with twofold
greater occurrence of bladder problems and fourfold
risk of other autonomic problems, when compared with
the controls115. The patients complained of urinary
frequency and urgency, but with little urinary output
each time. Prostate enlargement is common among
older patients. It usually becomes an obstacle for empty-
ing urine completely. Nocturnal urinary urgency is also
common. Many patients have the urge to urinate fre-
quently at night as their sleep becomes fragmented.
Urinary incontinence will occur if patients walk slowly
and cannot reach the bathroom in time. It seems that
the severity of bladder dysfunction is correlated with the
progression of PD116. Appropriate dosage of anticholin-
ergics or alpha-blockers helps relieve the frequency prob-
lems. The use of dopaminergic medications to improve
bladder function has been reported but is generally
not reliable117,118.
Sexual dysfunctions, including erectile difficulty, loss
of libido, and anorgasmia, are common in male PD
patients119. Erectile dysfunction was nearly twice as
frequent in PD patients, compared with controls from a
questionnaire-based study115. Patients rarely give infor-
mation despite its significance on quality of life. Silde-
nafil has been reported to be effective for erectile
dysfunction in patients without obvious cardiovascu-
lar risk factors120–122. Other patients may suffer a com-
pletely opposite problem, which is sexual impulse
control. Patients, particularly those taking dopaminergic
medications, may become obsessive and compulsive
in gambling, shopping, spending or even sex. Pergolide
mesylate, when added to L-DOPA, was reported to sig-
nificantly improve all sexual functions in younger male
PD patients who were still interested in sexual activi-
ties123. However, some argued that dopamine agonists
may induce impulse control disorders in PD, resulting
in hypersexuality in these patients124,125. Dopamine
agonists did not actually improve erectile dysfunction in
these patients. The effects of impulse control difficulties
on PD patients will need further investigation.
Thermoregulation
PD patients may experience cold or heat intolerance.
A more common problem is excessive sweating
(hyperhidrosis). A study found that complaints of
sweating disturbances were not correlated with dis-
ease severity but did correlate with other symptoms of
autonomic dysfunction. Sweating problems occurred
predominantly in “off” periods and in “on” periods with
dyskinesias. It was almost three times more common
than in controls who did not have PD126. Excessive
sweating occurred mainly on the face, head, and trunk.
It may be explained by decreased activation of sweat
glands in the palms of the hands, suggesting that axial
hyperhidrosis can be a compensatory phenomenon
for reduced sympathetic function in the extremities127.
This phenomenon results in reduced quality of life of
the patients, in the areas of daily activities as well as
social interactions126. Botulinum toxin injections may
relieve local areas of hyperhidrosis, though it has no
effect on the body function or thermoregulation.
Conclusion
Non-motor symptoms in PD are usually more compli-
cated and difficult to manage than typical PD motor
symptoms. However, they are usually overlooked and
not properly treated. Physicians should be aware of
the need to evaluate the neuropsychiatric, cognitive,
autonomic, and sleep complications of PD. Early recog-
nition of non-motor symptoms is essential, as effective
treatment can reduce morbidity and improve the
quality of life of PD patients.
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